Connecticut is currently home to 1225 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Adaptation and Implementation of Peer Support in Brazil
NCT05842889
Recruiting
Mental disorders are among the leading causes of disability and morbidity worldwide, including Brazil, where despite having a comprehensive network of publicly-funded, free, community-based mental health treatment, it is estimated that only 26% of people with psychiatric conditions successfully connect to community-based care. The study team hypothesizes that the successful adaptation and implementation of an evidence-based model of peer support to Brazilian culture, will contribute to enhanced... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Yale University Program for Recovery and Community Health, New Haven, Connecticut
Conditions: Peer Support
Register for Updates
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Conventional Chondrosarcoma
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport, Connecticut
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Novel physIologiC prEdictors of Positive Airway Pressure Effectiveness
NCT05067088
Recruiting
Millions of Americans suffer from high blood pressure, diabetes, strokes and motor vehicle accidents due to ineffective treatment of obstructive sleep apnea (OSA). Our preliminary data suggest that physiological causes of OSA such as easy arousability (low arousal threshold) or unstable breathing control (high loop gain) may influence effectiveness of OSA's most common treatment, continuous positive airway pressure (CPAP). The NICE-PAP study will examine how the physiologic traits that cause OSA... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
01/08/2025
Locations: Yale New Haven Hospital Sleep Center, North Haven, Connecticut
Conditions: Obstructive Sleep Apnea
Register for Updates
Mechanistic Studies of Psilocybin in Headache Disorders
NCT06464367
Recruiting
In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect. This study will measure brain resting state functional connectivity (fMRI), central synaptic density (SV2A PET), peripheral markers of inflammation, circadian rhythm (actigraphy), and sleep (sleep EEG) in both migraine and healthy control participants before and one week after the... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
01/07/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Migraine
Register for Updates
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
NCT04251416
Recruiting
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut
Conditions: Endometrial Carcinoma
Register for Updates
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
NCT06082960
Recruiting
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors * Identify the maximum tolerated dose (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut
Conditions: Solid Tumors
Register for Updates
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304
Recruiting
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
01/06/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
MagnetOs Flex Matrix Compared to Trinity Elite Mixed with Local Autograft in Patients Undergoing Up to Four-level Instrumented Posterolateral Fusion
NCT05037968
Recruiting
This is a phase IV post-marketing study for MagnetOs Flex Matrix. MagnetOs Flex Matrix is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease and undergoing spinal fusion surgery. In this study, MagnetOs Flex Matrix will be used according to the latest U.S. Instructions For Use, specifically as a bone graft extender mixed with autograft in a 1:1 vol.% in the posterolateral spine. Trinity Elite will also be used a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Degenerative Disc Disease, Spine Fusion, Leg Pain and/or Back Pain
Register for Updates
Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae
NCT03506308
Recruiting
This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter in subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Arteriovenous Fistula
Register for Updates
RCT to Evaluate Social Skills in Children with Autism Using VR Technology (SoCaVR)
NCT06453629
Recruiting
The goal of this randomized clinical trial is to compare and learn about Virtual Reality (VR) in children with autism/Autistic children. The main question it aims to answer is: • Does the Floreo VR clinical product show clinical improvement in autism symptoms? Participants will engage the VR product for twice a week for twelve weeks. They will be randomized to either the Floreo Clinical Product or a VR Control group experience. Researchers will compare the two groups to see if there is an e... Read More
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
01/02/2025
Locations: Cortica- Ridgefield, Ridgefield, Connecticut
Conditions: Autism Spectrum Disorder, Social Communication
Register for Updates
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063
Recruiting
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.
Gender:
FEMALE
Ages:
Between 15 years and 55 years
Trial Updated:
01/02/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Cesarean Delivery, General Anesthesia
Register for Updates